MannKind (MNKD) Revenue & Revenue Breakdown
MannKind Revenue Highlights
Latest Revenue (Y)
$198.96M
Latest Revenue (Q)
$66.26M
Main Segment (Y)
License and Service
MannKind Revenue by Period
MannKind Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $198.96M | 99.42% |
| 2022-12-31 | $99.77M | 32.25% |
| 2021-12-31 | $75.44M | 15.81% |
| 2020-12-31 | $65.14M | 3.34% |
| 2019-12-31 | $63.04M | 126.28% |
| 2018-12-31 | $27.86M | 137.20% |
| 2017-12-31 | $11.74M | -93.28% |
| 2016-12-31 | $174.76M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2012-12-31 | $35.00K | -30.00% |
| 2011-12-31 | $50.00K | -46.24% |
| 2010-12-31 | $93.00K | 100.00% |
| 2009-12-31 | - | -100.00% |
| 2008-12-31 | $20.00K | 100.00% |
| 2007-12-31 | $10.00K | -90.00% |
| 2006-12-31 | $100.00K | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | 100.00% |
| 2003-12-31 | - | 100.00% |
| 2002-12-31 | - | -100.00% |
| 2001-12-31 | $326.00K | 111.69% |
| 2000-12-31 | $154.00K | - |
MannKind generated $198.96M in revenue during NA 2023, up 99.42% compared to the previous quarter, and up 714.17% compared to the same period a year ago.
MannKind Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $66.26M | 13.32% |
| 2023-12-31 | $58.47M | 14.09% |
| 2023-09-30 | $51.25M | 5.43% |
| 2023-06-30 | $48.61M | 19.65% |
| 2023-03-31 | $40.63M | 12.67% |
| 2022-12-31 | $36.06M | 9.85% |
| 2022-09-30 | $32.83M | 73.73% |
| 2022-06-30 | $18.89M | 57.56% |
| 2022-03-31 | $11.99M | -4.18% |
| 2021-12-31 | $12.52M | -43.65% |
| 2021-09-30 | $22.21M | -4.59% |
| 2021-06-30 | $23.28M | 33.52% |
| 2021-03-31 | $17.44M | -5.46% |
| 2020-12-31 | $18.44M | 20.13% |
| 2020-09-30 | $15.35M | 1.57% |
| 2020-06-30 | $15.11M | -6.90% |
| 2020-03-31 | $16.23M | 1.51% |
| 2019-12-31 | $15.99M | 9.58% |
| 2019-09-30 | $14.60M | -2.71% |
| 2019-06-30 | $15.00M | -14.02% |
| 2019-03-31 | $17.45M | 8.83% |
| 2018-12-31 | $16.03M | 258.74% |
| 2018-09-30 | $4.47M | 14.80% |
| 2018-06-30 | $3.89M | 12.35% |
| 2018-03-31 | $3.46M | -23.51% |
| 2017-12-31 | $4.53M | 121.73% |
| 2017-09-30 | $2.04M | -5.55% |
| 2017-06-30 | $2.16M | -28.12% |
| 2017-03-31 | $3.01M | -75.74% |
| 2016-12-31 | $12.40M | -92.36% |
| 2016-09-30 | $162.35M | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | -100.00% |
| 2012-09-30 | $35.00K | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2011-03-31 | $50.00K | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | -100.00% |
| 2010-06-30 | $93.00K | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | -100.00% |
| 2008-03-31 | $20.00K | 100.00% |
| 2007-12-31 | - | - |
MannKind generated $66.26M in revenue during Q1 2024, up 13.32% compared to the previous quarter, and up 183.76% compared to the same period a year ago.
MannKind Revenue Breakdown
MannKind Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License and Service | $41.91M | - | - | - | - |
| Royalty | - | $15.60M | - | - | - |
| Service | - | $3.10M | - | - | - |
| Product Sales | - | $81.07M | - | - | - |
| Product | - | $56.25M | $39.17M | $32.32M | - |
| License And Service | - | - | $22.02M | $9.56M | $7.90M |
MannKind's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License And Service | $14.78M | $10.68M | $8.71M | $7.14M | $6.08M | $5.51M | $3.29M | $2.63M | $1.58M | $1.98M | $3.36M | $2.39M | $1.84M | $2.14M | - | - | - | - | - | - |
| License and Service | - | $22.64M | $10.26M | $9.01M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Service | - | - | - | - | - | $513.00K | $430.00K | $1.17M | - | - | - | - | - | - | - | - | - | - | - | - |
| Product Sales | - | - | - | - | - | $26.47M | $26.18M | $17.42M | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | - | - | - | $17.44M | $16.26M | $12.72M | $9.83M | $11.34M | $9.75M | $10.06M | $7.28M | - | - | - | - | - | - | - |
| Royalty | - | - | - | - | - | $9.07M | $6.22M | $304.00K | - | - | - | - | - | - | - | - | - | - | - | - |
MannKind's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: License And Service (100.00%).
MannKind Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| UTHR | United Therapeutics | $2.33B | $748.90M |
| TECH | Bio-Techne | $1.16B | $303.43M |
| LEGN | Legend Biotech | $285.14M | $93.99M |
| KNSA | Kiniksa Pharmaceuticals | $270.26M | $112.21M |
| MNKD | MannKind | $198.96M | $66.26M |
| SGMO | Sangamo Therapeutics | $176.23M | $356.00K |
| ADAP | Adaptimmune Therapeutics | $60.28M | $128.37M |
| LQDA | Liquidia | $17.49M | $2.97M |
| AFMD | Affimed | $8.28M | $155.00K |
| IMMP | Immutep | $3.51M | $2.11M |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| VSTM | Verastem | - | $10.00M |
| INKT | MiNK Therapeutics | - | - |
| PCVX | Vaxcyte | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| ELEV | Elevation Oncology | - | - |
| LRMR | Larimar Therapeutics | - | - |
| ACER | Acer Therapeutics | - | $371.79K |
| KTTA | Pasithea Therapeutics | - | - |
MNKD Revenue FAQ
What is MannKind’s yearly revenue?
MannKind's yearly revenue for 2023 was $198.96M, representing an increase of 99.42% compared to 2022. The company's yearly revenue for 2022 was $99.77M, representing an increase of 32.25% compared to 2021. MNKD's yearly revenue for 2021 was $75.44M, representing an increase of 15.81% compared to 2020.
What is MannKind’s quarterly revenue?
MannKind's quarterly revenue for Q1 2024 was $66.26M, a 13.32% increase from the previous quarter (Q4 2023), and a 63.10% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $58.47M, a 14.09% increase from the previous quarter (Q3 2023), and a 62.16% increase year-over-year (Q4 2022). MNKD's quarterly revenue for Q3 2023 was $51.25M, a 5.43% increase from the previous quarter (Q2 2023), and a 56.14% increase year-over-year (Q3 2022).
What is MannKind’s revenue growth rate?
MannKind's revenue growth rate for the last 3 years (2021-2023) was 163.73%, and for the last 5 years (2019-2023) was 215.62%.
What are MannKind’s revenue streams?
MannKind's revenue streams in c 23 are License and Service
What is MannKind’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of MannKind was License and Service. This segment made a revenue of $41.91M, representing 100.00% of the company's total revenue.